Search results for "neuroblastoma."
showing 10 items of 238 documents
The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …
2021
Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…
Gamma enolase expression as early marker of neuronal differentiation of murine neuroblastoma cells N-115
2012
In this study we determined the levels of gamma enolase mRNA in mouse neuroblastoma cell line N-115 at early period of induction of differentiation by serum withdrawal. The expression of gamma enolase was examined by Northern blot analysis of total RNA extracted from cells induced for different lengths of time. We found a 3-fold increase in the level of gamma enolase mRNA after 24 hours of induction of differentiation and higher levels were detected in cells induced for longer time, reaching a 10-fold increase after four days.
A Comprehensive Tissue Microarray-Based FISH Screen of ALK Gene in Neuroblastomas
2011
The heterogeneity of neuroblastic tumors added to the immense biological complexity has led to an unprecedented scale of investigations and a growing list of molecular genetic targets for prognosis as well as therapy. Recently, Anaplastic Lymphoma Kinase (ALK) has been identified as a major predisposing gene as well as a potential therapeutic target for neuroblastoma. Individuals with ALK-related neuroblastoma susceptibility (i.e., heterozygous for an ALK mutation) are at risk of developing neuroblastic tumors. Aberrant copy number or mutations in ALK gene and overexpression of its protein tyrosine-kinase receptor have been related to poor prognosis of this disease, although a great degree …
MBP-1 represses N-MYC expression and acts as a tumor suppressor in human Neuroblastoma LAN-5 cells
2013
Neuroblastoma is the most common extra-cranial solid tumor of childhood, originated from cells of the neural crest. Amplification of N-MYC gene and 1p-deletion are found in more than 30% of patients with advanced stages and they are associated with poor prognosis. An alternative translated product of the ENO1 gene, known as MBP-1 (c-myc promoter binding protein-1), acts as a negative regulator of the c-MYC oncogene, ERBB2 and COX-2 genes, furthermore, ENO1/MBP-1 overexpression in Neuroblastoma cells significantly reduces cell growth and induces apoptosis. Even though there are similarities between the c-MYC and N-MYC oncogenes, there are no evidences that MBP-1 is able to interact with N-MY…
MBP-1 reprime l’espressione di N-MYC e svolge il ruolo di oncosoppressore in cellule di Neuroblastoma umano LAN5
2013
Il Neuroblastoma, derivato da cellule neurali simpatiche primitive, è il tumore solido extracranico più comune dell'infanzia. L'amplificazione del gene N-MYC insieme a delezioni nel cromosoma 1p36, sono i marcatori molecolari più frequenti nel Neuroblastoma e sono associati a cattiva prognosi. MBP-1, prodotto alternativo della traduzione dell'mRNA del gene ENO1, è un repressore trascrizionale e agisce direttamente sul promotore dei geni c-MYC, ERBB2 e COX2 (1-3). In cellule di Neuroblastoma è stato osservato che l'espressione ectopica di ENO1/MBP-1 causa induzione di apoptosi e morte cellulare (4). Sebbene esistano similarità di struttura e funzionali tra i geni N-MYC e c-MYC non è noto se …
CURCUMIN ENTRAPPED INTO LIPID NANOSYSTEMS IMPROVES INHIBITION OF NEUROBLASTOMA CANCER CELL GROWTH ACTIVATING HSP70 PROTEIN
2010
Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen.
2009
Complex regional pain syndrome, which is characterised by pain and trophic disturbances, develops frequently after peripheral limb trauma. There is an increasing evidence of an involvement of the immune system in CRPS, and recently we showed that CRPS patients have autoantibodies against nervous system structures. Therefore we tested the sera of CRPS patients, neuropathy patients and healthy volunteers for surface-binding autoantibodies to primary cultures of autonomic neurons and differentiated neuroblastoma cell lines using flow cytometry. Thirteen of 30 CRPS patients, but none of 30 healthy controls and only one of the 20 neuropathy sera had specific surface binding to autonomic neurons …
Investigating the Role of Guanosine on Human Neuroblastoma Cell Differentiation and the Underlying Molecular Mechanisms
2021
Neuroblastoma arises from neural crest cell precursors failing to complete the process of differentiation. Thus, agents helping tumor cells to differentiate into normal cells can represent a valid therapeutic strategy. Here, we evaluated whether guanosine (GUO), a natural purine nucleoside, which is able to induce differentiation of many cell types, may cause the differentiation of human neuroblastoma SH-SY5Y cells and the molecular mechanisms involved. We found that GUO, added to the cell culture medium, promoted neuron-like cell differentiation in a time- and concentration-dependent manner. This effect was mainly due to an extracellular GUO action since nucleoside transporter inhibitors r…
Abstract 448: Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: Feasibility study
2014
Abstract Introduction There are numerous causes triggering CRC. 25-80% of CRC shown a deregulation in Epidermal Growth Factor Receptor (EGFR) pathway. Two signaling pathways downstream of the EGFR are dysregulated in CRC the mitogen-activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K) pathway. Activating mutations in KRAS and BRAF (MAPK pathway) and PIK3CA affect prognosis and/or response to anti-EGFR MoAb. PTEN is a downstream effector of EGFR pathway and is involved in PI3K pathway. Loss of PTEN protein expression can occur through epigenetic silencing and mutation or allelic loss. Immunohistochemistry (IHC) is the most effective way to assay for loss of PTEN expressio…
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…
2021
This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.